Sera Prognostics PreTRM Test
Sera Prognostics has announced a program for limited commercial access to PreTRM, a proteomic biomarker blood test designed to provide an early, objective, and individualized assessment of a woman's risk of preterm birth. The test will be made available in limited locations in the US, beginning with selected clinical sites that participated in the Proteomic Assessment of Preterm Risk study. All testing will be conducted at Sera's CLIA-certified laboratory in response to orders from women's healthcare professionals. Following the early access outreach to physicians in selected markets this fall, Sera is planning for a wider national PreTRM rollout in 2016, the company said in a statement.